Evidence map›Paper›PMID 34281421›Full record

ArticleInternational journal of toxicology2021

Evaluation of the AV7909 Anthrax Vaccine Toxicity in Sprague Dawley Rats Following Three Intramuscular Administrations.

Veena V Rao, C Steven Godin, Michael J Lacy, Jon R Inglefield, Sukjoon Park, Bruna Blauth, Joshua J Reece, Boris Ionin, Vladimir Savransky

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Human anthrax vaccines: Current status and future prospects.Human vaccines & immunotherapeutics · 2025
    Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Veena V Rao61424Emergent BioSolutions Inc, Gaithersburg, MD, USA.
C Steven GodinInotiv, Gaithersburg, MD, USA.
Michael J Lacy61424Emergent BioSolutions Inc, Gaithersburg, MD, USA.
Jon R Inglefield437329Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Sukjoon Park61424Emergent BioSolutions Inc, Gaithersburg, MD, USA.
Bruna Blauth61424Emergent BioSolutions Inc, Gaithersburg, MD, USA.
Joshua J Reece61424Emergent BioSolutions Inc, Gaithersburg, MD, USA.
Boris Ionin61424Emergent BioSolutions Inc, Gaithersburg, MD, USA.
Vladimir Savransky61424Emergent BioSolutions Inc, Gaithersburg, MD, USA.ORCID 0000-0002-6458-2690
Emergent BioSolutions (United States) · USFrederick National Laboratory for Cancer Research · US

Funding

Development of a Next Generation Anthrax Vaccine, AV7909U01AI078169 · NIAID · EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR · PI PARK, SUKJOON · 2008 to 2012
$2.8M
NIAID NIH HHS U01 AI078169
6 · The paper itself

Abstract

AV7909 is a next-generation anthrax vaccine under development for post-exposure prophylaxis following suspected or confirmed

Indexed as

Adjuvants, ImmunologicAnimalsAnthrax VaccinesAntibodies, BacterialAntibodies, NeutralizingAntigens, BacterialBacterial ToxinsFemaleInjections, IntramuscularInjection Site ReactionMaleMuscle, SkeletalOligodeoxyribonucleotidesPost-Exposure ProphylaxisRatsRats, Sprague-DawleyAdjuvants, Immunologicanthrax toxinAnthrax VaccinesAntibodies, BacterialAntibodies, NeutralizingAntigens, BacterialBacterial ToxinsOligodeoxyribonucleotidesProMuneanimalanthraxAV7909CPG 7909ratstoxicityvaccine

Identifiers

PMID34281421
PMCPMC8532110
OpenAlexW3183991911

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.